The notorious R.N.A. in the spotlight - drug or target for the treatment of disease

References

• Klungland A, Dahl JA. Dynamic RNA modifications in disease. Curr Opin Genet Dev 2014; 26:47-52; PMID:25005745; http://dx.doi.org/10.1016/j.gde.2014.05.006
   PubMed Web of Science ®Google Scholar
• Schoenberg DR, Maquat LE. Regulation of cytoplasmic mRNA decay. Nat Rev Genet 2012; 13:246-59; PMID:22392217; http://dx.doi.org/10.1038/nrg3254
   PubMed Web of Science ®Google Scholar
• Chabot B, Shkreta L. Defective control of pre-messenger RNA splicing in human disease. J Cell Biol 2016; 212:13-27; PMID:26728853; http://dx.doi.org/10.1083/jcb.201510032
   PubMed Web of Science ®Google Scholar
• Scheper GC, van der Knaap MS, Proud CG. Translation matters: protein synthesis defects in inherited disease. Nat Rev Genet 2007; 8:711-23; PMID:17680008; http://dx.doi.org/10.1038/nrg2142
   PubMed Web of Science ®Google Scholar
• Nalavade R, Griesche N, Ryan DP, Hildebrand S, Krauss S. Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis 2013; 4:e752; PMID:23907466; http://dx.doi.org/10.1038/cddis.2013.276
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50:259-93; PMID:20055705; http://dx.doi.org/10.1146/annurev.pharmtox.010909.105654
   PubMed Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11:125-40; PMID:22262036; http:dx.doi.org/10.1038/nrd3625
   PubMed Web of Science ®Google Scholar
• Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009; 5:381-91; PMID:19379126; http://dx.doi.org/10.1517/17425250902877680
   PubMed Web of Science ®Google Scholar
• Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015; 21:121-31; PMID:25654603; http://dx.doi.org/10.1038/nm.3793
   PubMed Web of Science ®Google Scholar
• Myra Stern and Eric WFW Alton. Use of Liposomes in the Treatment of Cystic Fibrosis. Gene Therapy in Lung Disease CRC Press, 2002; 383–396; http://dx.doi.org/10.3109/9780203908822-18
   Google Scholar
• Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21:492-7; PMID:25849132; http://dx.doi.org/10.1038/nm.3847
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11; PMID:9486653; http://dx.doi.org/10.1038/35888
   PubMed Web of Science ®Google Scholar
• Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004; 279:17181-9; PMID:14960586; http://dx.doi.org/10.1074/jbc.M311683200
   PubMed Web of Science ®Google Scholar
• Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:467-74; PMID:11931780; http://dx.doi.org/10.1016/S0002-9394(02)01327-2
   PubMed Web of Science ®Google Scholar
• Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002; 133:475-83; PMID:11931781; http://dx.doi.org/10.1016/S0002-9394(02)01326-0
   PubMed Web of Science ®Google Scholar
• Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:484-98; PMID:11931782; http://dx.doi.org/10.1016/S0002-9394(02)01332-6
   PubMed Web of Science ®Google Scholar
• Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterol J 2016; 4:97-104; PMID:26966529; http://dx.doi.org/10.1177/2050640615593681
   PubMed Web of Science ®Google Scholar
• Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis. (2015). Clinical Phase Trial III
   Google Scholar
• Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, Ferry A, Conduzorgues JP, Hadri A, Cursiefen C, et al. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 2012; 53:1195-203; PMID:22323484; http://dx.doi.org/10.1167/iovs.11-9064
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Viaud E, Bock F, Geudelin B, Ferry A, Kadlecová P, Lévy M, Al Mahmood S, Colin S, Thorin E, et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study. Ophthalmology 2014; 121:1683-92; PMID:24811963; http://dx.doi.org/10.1016/j.ophtha.2014.03.038
   PubMed Web of Science ®Google Scholar
• A multicentre double-blind randomized study to investigate the efficacy and tolerability of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularization, a major risk factor of corneal graft rejection: The I-GRAFT study. (2009). Clinical Trial Phase III
   Google Scholar
• The STRONG Study. (http://strong-nvg.com/the-study/). Clinical Trial Phase II/III
   Google Scholar
• Yoon H, Kim DJ, Ahn EH, Gellert GC, Shay JW, Ahn CH, Lee YB. Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 2009; 108:832-8; PMID:19693774; http://dx.doi.org/10.1002/jcb.22311
   PubMed Web of Science ®Google Scholar
• A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer. (2009). Clinical Trial Phase II
   Google Scholar
• Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer. (2014). Clinical Trial Phase IB/II
   Google Scholar
• Tagawa ST, Chatta GS, Mazhari R, Benaim E. Archexin, a novel AKT-1-specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data. ASCO Annual Meeting Proceedings 2016; (suppl 2S; abstr 550);
   Google Scholar
• MacLeod AR. Antisense therapies for cancer: bridging the pharmacogenomic divide. Drug Discovery Today: Therapeutic Strategies 2013; 10:e157-e63
   Google Scholar
• Teplova M, Minasov G, Tereshko V, Inamati GB, Cook PD, Manoharan M, Egli M. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat Struct Mol Biol 1999; 6:535-9; PMID:10360355; http://dx.doi.org/10.1038/9304.
   Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet 2010; 375:998-1006; http://dx.doi.org/10.1016/S0140-6736(10)60284-X
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126:2283-92; PMID:23060426; http://dx.doi.org/10.1161/CIRCULATIONAHA.112.104125
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2015; 36:566-75; PMID:24366918; http://dx.doi.org/10.1093/eurheartj/eht549
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19:43-4; PMID:22494066; http://dx.doi.org/10.3109/13506129.2012.673140
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy. (2012). Clinical Phase trial II/III
   Google Scholar
• Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP). (2012). Clinical Phase Trial III
   Google Scholar
• Ionis Pharmaceuticals Press Release. (http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID2105651). 2015
   Google Scholar
• Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY). (2010). Clinical Trial Phase III
   Google Scholar
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY). (2012). Clinical Trial Phase III
   Google Scholar
• OncoGenex Press Release. (http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=933276). 2015
   Google Scholar
• Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2012; 7:579-86; PMID:22198426; http://dx.doi.org/10.1097/JTO.0b013e31823f459c
   PubMed Web of Science ®Google Scholar
• A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. (2012). Clinical Trial Phase III
   Google Scholar
• Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, Prakash TP, Migawa MT, Bhat B, Swayze EE. Synthesis and biophysical evaluation of 2′, 4′-constrained 2′ O-methoxyethyl and 2′, 4′-constrained 2′ O-ethyl nucleic acid analogues. J Org Chem 2010; 75:1569-81; PMID:20136157; http://dx.doi.org/10.1021/jo902560f
   PubMed Web of Science ®Google Scholar
• Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Translat Med 2015; 7:314ra185-314ra185; http://dx.doi.org/10.1126/scitranslmed.aac5272
   PubMed Web of Science ®Google Scholar
• AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites. (2015). Clinical Trial Phase II
   Google Scholar
• Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck. (2015). Clinical Trial Phase IB/II
   Google Scholar
• Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers. (2012). Clinical Trial Phase I/II
   Google Scholar
• MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023). (2015). Clinical Trial Phase IB
   Google Scholar
• Prakash PT, Seth PP, Swayze EE, Graham MJ. Compositions and methods for modulating apolipoprotein (a) expression (US. Patent No. Nine,181,550). 2015
   Google Scholar
• Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014; 136:16958-61; PMID:25434769; http://dx.doi.org/10.1021/ja505986a
   PubMed Web of Science ®Google Scholar
• Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 2014; 42:8796-807; PMID:24992960; http://dx.doi.org/10.1093/nar/gku531
   PubMed Web of Science ®Google Scholar
• Ionis Pharmaceuticals Press Release. (http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2110180) 2015
   Google Scholar
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a). (2015). Clinical Trial Phase I
   Google Scholar
• Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919-28; PMID:3319190; http://dx.doi.org/10.1016/0092-8674(87)90579-4
   PubMed Web of Science ®Google Scholar
• Aartsma‐Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT. Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30:293-9; PMID:19156838; http://dx.doi.org/10.1002/humu.20918
   PubMed Web of Science ®Google Scholar
• Koenig M, Beggs A, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Müller CR, Lindlöf M, Kaariainen H, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989; 45:498; PMID:2491009
   PubMed Web of Science ®Google Scholar
• Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014; 13:987-96; PMID:25209738; http://dx.doi.org/10.1016/S1474-4422(14)70195-4
   PubMed Web of Science ®Google Scholar
• A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects. (2013). Clinical Trial Phase III
   Google Scholar
• Extension Study of Drisapersen in DMD Subjects. (2015). Clinical Trial Phase IIIB
   Google Scholar
• Mendell JR, Rodino‐Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74:637-47; PMID:23907995; http://dx.doi.org/10.1002/ana.23982
   PubMed Web of Science ®Google Scholar
• Confirmatory Study of Eteplirsen in DMD Patients (PROMOVI). (2014). Clinical Trial Phase III
   Google Scholar
• Drisapersen FDA Report. (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM473737.pdf). 2015
   Google Scholar
• Komaki H, Nagata T, Saito T, Masuda S, Takeshita E, Tachimori H, et al. GP 251-Exon 53 skipping of the dystrophin gene in patients with Duchenne muscular dystrophy by systemic administration of NS-065/NCNP-01: A phase 1, dose escalation, first-in-human study. Neuromuscular Disorders 2015; 25:S261-S2; http://dx.doi.org/10.1016/j.nmd.2015.06.276
   Web of Science ®Google Scholar
• Nippon Shinyaku Press Release. (https://www.nippon-shinyaku.co.jp/english/news/?id=2920). 2016
   Google Scholar
• Koizumi M. 2′-O, 4′-C-Ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents. Biol Pharm Bull 2004; 27:453-6; PMID:15056846; http://dx.doi.org/10.1248/bpb.27.453
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Press Release. (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006412/160225_635_E.pdf). 2016
   Google Scholar
• Study of DS-5141b in Patients With Duchenne Muscular Dystrophy. (2016). Clinical Trial Phase I/II
   Google Scholar
• Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80:155-65; PMID:7813012; http://dx.doi.org/10.1016/0092-8674(95)90460-3
   PubMed Web of Science ®Google Scholar
• Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999; 96:6307-11; PMID:103395583; http://dx.doi.org/10.1073/pnas.96.11.6307
   PubMed Web of Science ®Google Scholar
• Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008; 82:834-48; PMID:18371932; http://dx.doi.org/10.1016/j.ajhg.2008.01.014
   PubMed Web of Science ®Google Scholar
• Ionis Pharmaceuticals. (http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2097778). 2015
   Google Scholar
• A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants With Spinal Muscular Atrophy. (2014). Clinical Trial Phase III
   Google Scholar
• A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Patients With Later-onset Spinal Muscular Atrophy. (2014). Clinical Phase Trial III
   Google Scholar
• Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, Khoo B. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 2014; 25:587-98; PMID:24826963; http://dx.doi.org/10.1089/hum.2013.234
   PubMed Web of Science ®Google Scholar
• Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9:537-50; PMID:20592747; http://dx.doi.org/10.1038/nrd3141
   PubMed Web of Science ®Google Scholar
• Bouchard PR, Hutabarat RM, Thompson KM. Discovery and Development of Therapeutic Aptamers. Annu Rev Pharmacol Toxicol 2010; 50:237-57; PMID:20055704; http://dx.doi.org/10.1146/annurev.pharmtox.010909.105547
   PubMed Web of Science ®Google Scholar
• Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjić N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273:20556-67; PMID:9685413; http://dx.doi.org/10.1074/jbc.273.32.20556
   PubMed Web of Science ®Google Scholar
• Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5:123-32; PMID:16518379; http://dx.doi.org/10.1038/nrd1955
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet 2016; 387:349-56; PMID:26547100; http://dx.doi.org/10.1016/S0140-6736(15)00515-2
   PubMed Web of Science ®Google Scholar
• A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate). (2013). Clinical Trial Phase III (Terminated)
   Google Scholar
• Dugel PU. Anti-PDGF combination therapy in neovascular age-related macular degeneration: results of a phase 2b study. Retina Today 2013; 8:65-71
   Google Scholar
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy. (2013). Clinical Trial Phase III
   Google Scholar
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy. (2013). Clinical Trial Phase III
   Google Scholar
• Monés J. Complement factor 5 inhibition in age-related macular degeneration. Retina Today 2010; 5:52-5
   Google Scholar
• A Phase 2/3 Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. (2016). Clinical Trial Phase II/III
   Google Scholar
• Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics. Drug Discovery Today 2015; 20:147-55; PMID:25236655; http://dx.doi.org/10.1016/j.drudis.2014.09.004
   PubMed Web of Science ®Google Scholar
• Ashley GW. Modeling, synthesis, and hybridization properties of (L)-ribonucleic acid. J Am Chem Soc 1992; 114:9731-6; http://dx.doi.org/10.1021/ja00051a001
   Web of Science ®Google Scholar
• van Eijk LT, John AS, Schwoebel F, Summo L, Vauléon S, Zöllner S, Laarakkers CM, Kox M, van der Hoeven JG, Swinkels DW, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 2014; 124:2643-6; PMID:25163699; http://dx.doi.org/10.1182/blood-2014-03-559484
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 2014; 9:118-28; PMID:25263552; http://dx.doi.org/10.1016/j.celrep.2014.08.042
   PubMed Web of Science ®Google Scholar
• NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma. (2012). Clinical Trial Phase IIA
   Google Scholar
• NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL). (2011). Clinical Trial Phase IIA
   Google Scholar
• Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C. Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun 2015; 6:6923; PMID:25901662; http://dx.doi.org/10.1038/ncomms7923
   PubMed Web of Science ®Google Scholar
• NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria. (2012). Clinical Trial Phase IIA
   Google Scholar
• Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer. (2012). Clinical Trial Phase IIA
   Google Scholar
• MacRae IJ, Ma E, Zhou M, Robinson CV, Doudna JA. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci U S A 2008; 105:512-7; PMID:18178619; http://dx.doi.org/10.1073/pnas.0710869105
   PubMed Web of Science ®Google Scholar
• Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics 2014; 2014:970607; PMID:25180174
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8; PMID:11373684; http://dx.doi.org/10.1038/35078107
   PubMed Web of Science ®Google Scholar
• Mellitzer G, Hallonet M, Chen L, Ang SL. Spatial and temporal ‘knock down’ of gene expression by electroporation of double-stranded RNA and morpholinos into early postimplantation mouse embryos. Mech Dev 2002; 118:57-63; PMID:12351170; http://dx.doi.org/10.1016/S0925-4773(02)00191-0
   PubMed Web of Science ®Google Scholar
• Calegari F, Haubensak W, Yang D, Huttner WB, Buchholz F. Tissue-specific RNA interference in postimplantation mouse embryos with endoribonuclease-prepared short interfering RNA. Proc Natl Acad Sci U S A 2002; 99:14236-40; PMID:12391321; http://dx.doi.org/10.1073/pnas.192559699
   PubMed Web of Science ®Google Scholar
• Zeliadt N. Big pharma shows signs of renewed interest in RNAi drugs. Nat Med 2014; 20:109; PMID:24504395; http://dx.doi.org/10.1038/nm0214-109
   PubMed Web of Science ®Google Scholar
• Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5. (2004). Clinical Trial Phase I
   Google Scholar
• A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004). (2008). Clinical Trial Phase I (Terminated)
   Google Scholar
• Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT). (2007). Clinical Trial Phase III (Terminated)
   Google Scholar
• Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS). (2008). Clinical Trial Phase II (Terminated)
   Google Scholar
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol. (2009). Clinical Trial Phase I (Terminated)
   Google Scholar
• A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration. (2006). Clinical Trial Phase II (Terminated)
   Google Scholar
• Conde J, Artzi N. Are RNAi and miRNA therapeutics truly dead? Trends Biotechnol 2015; 33:141-4; PMID:25595555; http://dx.doi.org/10.1016/j.tibtech.2014.12.005
   PubMed Web of Science ®Google Scholar
• Krieg AM. Is RNAi dead? Mol Ther 2011; 19:1001-2; PMID:21629254; http://dx.doi.org/10.1038/mt.2011.94
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369:819-29; PMID:23984729; http://dx.doi.org/10.1056/NEJMoa1208760
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383:60-8; PMID:24094767; http://dx.doi.org/10.1016/S0140-6736(13)61914-5
   PubMed Web of Science ®Google Scholar
• van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 34:1393-7; PMID:16714375; http://dx.doi.org/10.1124/dmd.106.009555
   PubMed Web of Science ®Google Scholar
• Alagia A, Eritja R. siRNA and RNAi optimization. Wiley interdisciplinary reviews RNA, 2016 7; 316-329; PMID:26840434; http://dx.doi.org/10.1002/wrna.1337
   Google Scholar
• Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203:1-15; PMID:25660205; http://dx.doi.org/10.1016/j.jconrel.2015.02.003
   PubMed Web of Science ®Google Scholar
• Jeong EH, Kim H, Jang B, Cho H, Ryu J, Kim B, Park Y, Kim J, Lee JB, Lee H. Technological development of structural DNA/RNA-based RNAi systems and their applications. Adv Drug Deliv Rev 2016; 107:29-43; PMID:26494399; http://dx.doi.org/10.1016/j.addr.2015.10.008
   Web of Science ®Google Scholar
• Bramsen JB, Kjems J. Engineering small interfering RNAs by strategic chemical modification. Methods Mol Biol 2013; 942:87-109; PMID:23027047; http://dx.doi.org/10.1007/978-1-62703-119-6_5
   PubMedGoogle Scholar
• Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4). (2014). Clinical Trial Phase I
   Google Scholar
• Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy. (2015). Clinical Trial Phase II
   Google Scholar
• A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP). (2015). Clinical Trial Phase I
   Google Scholar
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). (2014). Clinical Trial Phase III
   Google Scholar
• A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients. (2014). Clinical Trial Phase I
   Google Scholar
• Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer (STMN1-LP). (2012). Clinical Trial Phase I
   Google Scholar
• APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery. (2014). Clinical Trial Phase I
   Google Scholar
• SYL040012, Treatment for Open Angle Glaucoma (SYLTAG). (2014). Clinical Trial Phase II
   Google Scholar
• Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). (2015). Clinical Trial Phase II/III
   Google Scholar
• Bobbin ML, Rossi JJ. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu Rev Pharmacol Toxicol 2016; 56:103-22; PMID:26738473; http://dx.doi.org/10.1146/annurev-pharmtox-010715-103633
   PubMed Web of Science ®Google Scholar
• Lam JK, Chow MY, Zhang Y, Leung SW. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids 2015; 4:e252; PMID:26372022; http://dx.doi.org/10.1038/mtna.2015.23
   PubMedGoogle Scholar
• Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C. (2014). Clinical Trial Phase II
   Google Scholar
• Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 2014; 52:445-51; PMID:24871972; http://dx.doi.org/10.1007/s12275-014-4267-x
   PubMed Web of Science ®Google Scholar
• MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC. (2015). Clinical Trial Phase I
   Google Scholar
• A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. (2013). Clinical Trial Phase I
   Google Scholar
• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx.doi.org/10.1126/science.1690918
   PubMed Web of Science ®Google Scholar
• Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 1992; 255:996-8; PMID:1546298; http://dx.doi.org/10.1126/science.1546298
   PubMed Web of Science ®Google Scholar
• Isaacs A, Cox RA, Rotem Z. Foreign nucleic acids as the stimulus to make interferon. Lancet 1963; 2:113-6; PMID:13956740; http://dx.doi.org/10.1016/S0140-6736(63)92585-6
   PubMed Web of Science ®Google Scholar
• Weissman D. mRNA transcript therapy. Expert Rev Vaccines 2015; 14:265-81; PMID:25359562; http://dx.doi.org/10.1586/14760584.2015.973859
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8; PMID:11607032; http://dx.doi.org/10.1038/35099560
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, Karikó K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010; 38:5884-92; PMID:20457754; http://dx.doi.org/10.1093/nar/gkq347
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16:1833-40; PMID:18797453; http://dx.doi.org/10.1038/mt.2008.200
   PubMed Web of Science ®Google Scholar
• Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity 2013; 38:855-69; PMID:23706667; http://dx.doi.org/10.1016/j.immuni.2013.05.007
   PubMed Web of Science ®Google Scholar
• Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165-75; PMID:16111635; http://dx.doi.org/10.1016/j.immuni.2005.06.008
   PubMed Web of Science ®Google Scholar
• Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011; 29:154-7; PMID:21217696; http://dx.doi.org/10.1038/nbt.1733
   PubMed Web of Science ®Google Scholar
• Karijolich J, Yu YT. Converting nonsense codons into sense codons by targeted pseudouridylation. Nature 2011; 474:395-8; PMID:21677757; http://dx.doi.org/10.1038/nature10165
   PubMed Web of Science ®Google Scholar
• Summer H, Gramer R, Droge P. Denaturing urea polyacrylamide gel electrophoresis (Urea PAGE). J Vis Exp 2009; PMID:19865070; http://dx.doi.org/10.3791/1485(2009)
   PubMedGoogle Scholar
• Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011; 39:e142; PMID:21890902; http://dx.doi.org/10.1093/nar/gkr695
   PubMed Web of Science ®Google Scholar
• Pasquinelli AE, Dahlberg JE, Lund E. Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA 1995; 1:957-67; PMID:8548660
   PubMed Web of Science ®Google Scholar
• Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA 2001; 7:1486-95; PMID:11680853; http://dx.doi.org/10.1017.S1355838201014078
   PubMed Web of Science ®Google Scholar
• Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007; 13:1745-55; PMID:17720878; http://dx.doi.org/10.1261/rna.701307
   PubMed Web of Science ®Google Scholar
• Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, Ludwig C, Schäfer F, Graf M, Wagner R. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS one 2011; 6:e17596; PMID:21408612; http://dx.doi.org/10.1371/journal.pone.0017596
   PubMed Web of Science ®Google Scholar
• Al-Saif M, Khabar KS. UU/UA dinucleotide frequency reduction in coding regions results in increased mRNA stability and protein expression. Mol Ther 2012; 20:954-9; PMID:22434136; http://dx.doi.org/10.1038/mt.2012.29
   PubMed Web of Science ®Google Scholar
• Weissman D, Kariko K. mRNA: Fulfilling the Promise of Gene Therapy. Mol Ther 2015; 23:1416-7; PMID:26321183; http://dx.doi.org/10.1038/mt.2015.138
   PubMed Web of Science ®Google Scholar
• Zubiaga AM, Belasco JG, Greenberg ME. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol 1995; 15:2219-30; PMID:7891716; http://dx.doi.org/10.1128/MCB.15.4.2219
   PubMed Web of Science ®Google Scholar
• Peixeiro I, Silva AL, Romao L. Control of human β-globin mRNA stability and its impact on β-thalassemia phenotype. Haematologica 2011; 96:905-13; PMID:21357703; http://dx.doi.org/10.3324/haematol.2010.039206
   PubMed Web of Science ®Google Scholar
• Waggoner SA, Liebhaber SA. Regulation of α-globin mRNA stability. Exp Biol Med (Maywood) 2003; 228:387-95; PMID:12671183
   PubMed Web of Science ®Google Scholar
• Withers JB, Beemon KL. The structure and function of the rous sarcoma virus RNA stability element. J Cell Biochem 2011; 112:3085-92; PMID:21769913; http://dx.doi.org/10.1002/jcb.23272
   PubMed Web of Science ®Google Scholar
• Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev 1991; 5:2108-16; PMID:1682219; http://dx.doi.org/10.1101/gad.5.11.2108
   PubMed Web of Science ®Google Scholar
• Peng J, Murray EL, Schoenberg DR. In vivo and in vitro analysis of poly(A) length effects on mRNA translation. Methods Mol Biol 2008; 419:215-30; PMID:18369986; http://dx.doi.org/10.1007/978-1-59745-033-1_15
   PubMedGoogle Scholar
• Balmayor ER, Geiger JP, Aneja MK, Berezhanskyy T, Utzinger M, Mykhaylyk O, Rudolph C, Plank C. Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats. Biomaterials 2016; 87:131-46; PMID:26923361; http://dx.doi.org/10.1016/j.biomaterials.2016.02.018
   PubMed Web of Science ®Google Scholar
• Elangovan S, Khorsand B, Do AV, Hong L, Dewerth A, Kormann M, Ross RD, Sumner DR, Allamargot C, Salem AK. Chemically modified RNA activated matrices enhance bone regeneration. J Control Release 2015; 218:22-8; PMID:26415855; http://dx.doi.org/10.1016/j.jconrel.2015.09.050
   PubMed Web of Science ®Google Scholar
• Plews JR, Li J, Jones M, Moore HD, Mason C, Andrews PW, Na J. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PloS one 2010; 5:e14397; PMID:21209933; http://dx.doi.org/10.1371/journal.pone.0014397
   PubMed Web of Science ®Google Scholar
• Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7:618-30; PMID:20888316; http://dx.doi.org/10.1016/j.stem.2010.08.012
   PubMed Web of Science ®Google Scholar
• Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc 2013; 8:568-82; PMID:23429718; http://dx.doi.org/10.1038/nprot.2013.019
   PubMed Web of Science ®Google Scholar
• Preskey D, Allison TF, Jones M, Mamchaoui K, Unger C. Synthetically modified mRNA for efficient and fast human iPS cell generation and direct transdifferentiation to myoblasts. Biochem Biophys Res Commun 2015; PMID:26449459; http://dx.doi.org/10.1016/j.bbrc.2015.09.102
   PubMed Web of Science ®Google Scholar
• Simeonov KP, Uppal H. Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PloS One 2014; 9:e100134; PMID:24963715; http://dx.doi.org/10.1371/journal.pone.0100134
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 2012; 20:948-53; PMID:22334017; http://dx.doi.org/10.1038/mt.2012.7
   PubMed Web of Science ®Google Scholar
• Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32:551-3; PMID:24681508; http://dx.doi.org/10.1038/nbt.2884
   PubMed Web of Science ®Google Scholar
• Wang X, Yu H, Lei A, Zhou J, Zeng W, Zhu H, Niu Y, Shi B, Cai B, Liu J, et al. Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system. Sci Rep 2015; 5:13878; PMID:26354037; http://dx.doi.org/10.1038/srep13878
   PubMed Web of Science ®Google Scholar
• Kaneko T, Mashimo T. Simple Genome Editing of Rodent Intact Embryos by Electroporation. PloS one 2015; 10:e0142755; PMID:26556280; http://dx.doi.org/10.1371/journal.pone.0142755
   PubMed Web of Science ®Google Scholar
• Wang T, Hong Y. Direct gene disruption by TALENs in medaka embryos. Gene 2014; 543:28-33; PMID:24713411; http://dx.doi.org/10.1016/j.gene.2014.04.013
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang J, Xu J, Zhu T, Fan Y, Fan J, Chen YE. Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases. J Vis Exp 2013; 81; e50957; PMID:24301055; http://dx.doi.org/10.3791/50957
   PubMed Web of Science ®Google Scholar
• Flisikowska T, Thorey IS, Offner S, Ros F, Lifke V, Zeitler B, Rottmann O, Vincent A, Zhang L, Jenkins S, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PloS One 2011; 6:e21045; PMID:21695153; http://dx.doi.org/10.1371/journal.pone.0021045
   PubMed Web of Science ®Google Scholar
• Williams DA, Thrasher AJ. Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med 2014; 3:636-42; PMID:24682287; http://dx.doi.org/10.5966/sctm.2013-0206
   PubMed Web of Science ®Google Scholar
• Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008; 16:1609-16; PMID:18612271; http://dx.doi.org/10.1038/mt.2008.141
   PubMed Web of Science ®Google Scholar
• Mahiny AJ, Dewerth A, Mays LE, Alkhaled M, Mothes B, Malaeksefat E, Loretz B, Rottenberger J, Brosch DM, Reautschnig P, et al. In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat Biotechnol 2015; 33:584-6; PMID:25985262; http://dx.doi.or/10.1038/nbt.3241
   PubMed Web of Science ®Google Scholar
• Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117:2791-9; PMID:21148083; http://dx.doi.org/10.1182/blood-2010-09-309591
   PubMed Web of Science ®Google Scholar
• Evaluation the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT). (2015). Clinical Trial Phase I
   Google Scholar
• Wissink EM, Fogarty EA, Grimson A. High-throughput discovery of post-transcriptional cis-regulatory elements. BMC Genomics 2016; 17:177; PMID:26941072; http://dx.doi.org/10.1186/s12864-016-2479-7
   PubMed Web of Science ®Google Scholar
• Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012; 12:479-91; PMID:22728526; http://dx.doi.org/10.1038/nri3247
   PubMed Web of Science ®Google Scholar
• Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 2015; 33:257-90; PMID:25581309; http://dx.doi.org/10.1146/annurev-immunol-032414-112240
   PubMed Web of Science ®Google Scholar
• Clark GJ, Angel N, Kato M, Lopez JA, MacDonald K, Vuckovic S, Hart DN. The role of dendritic cells in the innate immune system. Microbes Infect 2000; 2:257-72; PMID:10758402; http://dx.doi.org/10.1016/S1286-4579(00)00302-6
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, et al. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 2016; 72:31-8; PMID:26751016; http://dx.doi.org/10.1097/QAI.0000000000000926
   PubMed Web of Science ®Google Scholar
• Weiss R, Scheiblhofer S, Thalhamer J. Allergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseases. Hum Vaccin Immunother 2014; 10:703-7; PMID:24280693; http://dx.doi.org/10.4161/hv.27183
   PubMed Web of Science ®Google Scholar
• Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol 2010; 10:567-74; PMID:20856111; http://dx.doi.org/10.1097/ACI.0b013e32833fd5b6
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011; 34:1-15; PMID:21150709; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014; 9:180; PMID:25127546; http://dx.doi.org/10.1186/1748-717X-9-180
   PubMed Web of Science ®Google Scholar
• Schmidt MA, Goodwin TJ. Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance. Metabolomics 2013; 9:1134-56; PMID:24273472; http://dx.doi.org/10.1007/s11306-013-0556-3
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012; 30:1210-6; PMID:23159882; http://dx.doi.org/10.1038/nbt.2436
   PubMed Web of Science ®Google Scholar
• Pascolo S. Vaccination with messenger RNA. Methods Mol Med 2006; 127:23-40; PMID:16988444; htpp://dx.doi.org/10.1385/1-59745-168-1:23
   PubMedGoogle Scholar
• Mortimer I, Tam P, MacLachlan I, Graham RW, Saravolac EG, Joshi PB. Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Ther 1999; 6:403-11; PMID:10435090; http://dx.doi.org/10.1038/sj.gt.3300837
   PubMed Web of Science ®Google Scholar
• Wong SS, Webby RJ. An mRNA vaccine for influenza. Nat Biotechnol 2012; 30:1202-4; PMID:23222788; http://dx.doi.org/10.1038/nbt.2439
   PubMed Web of Science ®Google Scholar
• Ichino M, Mor G, Conover J, Weiss WR, Takeno M, Ishii KJ, Klinman DM. Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J Immunol 1999; 162:3814-8; PMID:10201898
   PubMed Web of Science ®Google Scholar
• Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003; 134:378-84; PMID:14632740; http://dx.doi.org/10.1046/j.1365-2249.2003.02286.x
   PubMed Web of Science ®Google Scholar
• Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; http://dx.doi.org/10.1007/s00262-013-1453-3
   PubMed Web of Science ®Google Scholar
• Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012; 26:F1-12; PMID:22156965; http://dx.doi.org/10.1097/QAD.0b013e32834f33e8
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368
   PubMed Web of Science ®Google Scholar
• Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60:809-18; PMID:21365467; http://dx.doi.org/10.1007/s00262-011-0991-9
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/pnas.1008051107
   PubMed Web of Science ®Google Scholar
• Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134:140-7; PMID:19889582; http://dx.doi.org/10.1016/j.clim.2009.09.009
   PubMed Web of Science ®Google Scholar
• Coosemans A, Wolfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res 2010; 30:3709-14; PMID:20944158
   PubMed Web of Science ®Google Scholar
• Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT). (2012). Clinical Trial Phase III
   Google Scholar
• Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. J Clin Oncol 2016; 34:1330-8; PMID:26926680; http://dx.doi.org/10.1200/JCO.2015.63.4121
   PubMed Web of Science ®Google Scholar
• Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 2015; 4:e1019197; PMID:26405571; http://dx.doi.org/10.1080/2162402X.2015.1019197
   PubMed Web of Science ®Google Scholar
• MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT (PSCT19). (2016). Clinical Trial Phase II
   Google Scholar
• Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients (ADDIT-GLIO). (2016). Clinical Trial Phase II
   Google Scholar
• Autologous Dendritic Cell Vaccination in Mesothelioma (MESODEC). (2016). Clinical Trial Phase II
   Google Scholar
• Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II). (2016). Clinical Trial Phase II
   Google Scholar
• Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32:498-507; PMID:19609242; http://dx.doi.org/10.1097/CJI.0b013e3181a00068
   PubMed Web of Science ®Google Scholar
• RNActive® Rabies Vaccine (CV7201) in Healthy Adults. (2014). Clinical Trial Phase I
   Google Scholar
• Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2013; 2:e52; PMID:26038486; http://dx.doi.org/10.1038/emi.2013.54
   PubMed Web of Science ®Google Scholar
• Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC). (2013). Clinical Trial Phase I
   Google Scholar
• Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease. (2009). Clinical Trial Phase II
   Google Scholar
• Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer. (2013). Clinical Trial Phase II
   Google Scholar
• An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer. (2014). Clinical Trial Phase II
   Google Scholar
• IVAC MUTANOME Phase I Clinical Trial. (2014). Clinical Trial Phase I
   Google Scholar
• Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 2015; 137:372-84; PMID:25530186; http://dx.doi.org/10.1002/ijc.29402
   PubMed Web of Science ®Google Scholar
• CureVac Press Release. (http://www.curevac.com/fileadmin/curevac.de/media/Content/Newsroom/20151221_CureVac_Press_release_JP_Morgan.pdf). 2015
   Google Scholar
• Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR, Shi J. Biomaterials for mRNA delivery. Biomater Sci 2015; 3:1519-33; PMID:26280625; http://dx.doi.org/10.1039/C5BM00198F
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012; 109:14604-9; PMID:22908294; http://dx.doi.org/10.1073/pnas.1209367109
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gascon A, del Pozo-Rodriguez A, Solinis MA. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine 2014; 9:1833-43; PMID:24748793; http://dx.doi.org/10.2147/IJN.S39810
   PubMed Web of Science ®Google Scholar
• Xu J, Luft JC, Yi X, Tian S, Owens G, Wang J, Johnson A, Berglund P, Smith J, Napier ME, et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Mol Pharm 2013; 10:3366-74; PMID:23924216; http://dx.doi.org/10.1021/mp400190z
   PubMed Web of Science ®Google Scholar
• Pascolo S. The messenger's great message for vaccination. Expert Rev Vaccines 2015; 14:153-6; PMID:25586101; http://dx.doi.org/10.1586/14760584.2015.1000871
   PubMed Web of Science ®Google Scholar
• Hattinger E, Scheiblhofer S, Roesler E, Thalhamer T, Thalhamer J, Weiss R. Prophylactic mRNA Vaccination against Allergy Confers Long-Term Memory Responses and Persistent Protection in Mice. J Immunol Res 2015; 2015:797421; PMID:26557723; http://dx.doi.org/10.1155/2015/797421
   PubMed Web of Science ®Google Scholar
• Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993; 92:229-36; PMID:8349933; http://dx.doi.org/10.1016/0091-6749(93)90166-D
   PubMed Web of Science ®Google Scholar
• Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostbock S, Ferreira F, Thalhamer J, Scheiblhofer S. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009; 124:1070-7 e1-11; PMID:19665781; http://dx.doi.org/10.1016/j.jaci.2009.06.036
   PubMed Web of Science ®Google Scholar
• Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-36; PMID:10382766; http://dx.doi.org/10.1002/(SICI)1521-4141(199906)29:06%3c2026::AID-IMMU2026%3e3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Van Ree R, Van Leeuwen WA, Dieges PH, Van Wijk RG, De Jong N, Brewczyski PZ, Kroon AM, Schilte PP, Tan KY, Simon-Licht IF, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997; 27:68-74; PMID:9117883; http://dx.doi.org/10.1046/j.1365-2222.1997.d01-416.x
   PubMed Web of Science ®Google Scholar
• Stafforst T, Schneider MF. An RNA-deaminase conjugate selectively repairs point mutations. Angewandte Chemie 2012; 51:11166-9; PMID:23038402; http://dx.doi.org/10.1002/anie.201206489
   PubMedGoogle Scholar
• Schneider MF, Wettengel J, Hoffmann PC, Stafforst T. Optimal guideRNAs for re-directing deaminase activity of hADAR1 and hADAR2 in trans. Nucleic Acids Res 2014; 42:e87; PMID:24744243; http://dx.doi.org/10.1093/nar/gku272
   PubMed Web of Science ®Google Scholar
• Montiel-Gonzalez MF, Vallecillo-Viejo I, Yudowski GA, Rosenthal JJ. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc Natl Acad Sci U S A 2013; 110:18285-90; PMID:24108353; http://dx.doi.org/10.1073/pnas.1306243110
   PubMed Web of Science ®Google Scholar
• Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002; 71:817-46; PMID:12045112; http://dx.doi.org/10.1146/annurev.biochem.71.110601.135501
   PubMed Web of Science ®Google Scholar
• Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem 2010; 79:321-49; PMID:20192758; http://dx.doi.org/10.1146/annurev-biochem-060208-105251
   PubMed Web of Science ®Google Scholar
• Vogel P, Stafforst T. Site-directed RNA editing with antagomir deaminases–a tool to study protein and RNA function. ChemMedChem 2014; 9:2021-5; PMID:24954543; http://dx.doi.org/10.1002/cmdc.201402139
   PubMed Web of Science ®Google Scholar
• Vogel P, Schneider MF, Wettengel J, Stafforst T. Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angewandte Chemie 2014; 53:6267-71; PMID:24890431; http://dx.doi.org/10.1002/anie.201402634
   PubMedGoogle Scholar
• Hanswillemenke A, Kuzdere T, Vogel P, Jékely G, Stafforst T. Site-Directed RNA Editing in Vivo Can Be Triggered by the Light-Driven Assembly of an Artificial Riboprotein. J Am Chem Soc 2015; 137:15875-81; PMID:26594902; http://dx.doi.org/10.1021/jacs.5b10216
   PubMed Web of Science ®Google Scholar
• Zhao X, Yu Y-T. Targeted pre-mRNA modification for gene silencing and regulation. Nat Methods 2008; 5:95-100; PMID:18066073; http://dx.doi.org/10.1038/nmeth1142
   PubMed Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11:125-40; PMID:22262036; http://dx.doi.org/10.1038/nrd3625
   PubMed Web of Science ®Google Scholar
• Blanc V, Davidson NO. C-to-U RNA editing: mechanisms leading to genetic diversity. J Biol Chem 2003; 278:1395-8; PMID:12446660; http://dx.doi.org/10.1074/jbc.R200024200
   PubMed Web of Science ®Google Scholar
• Liu N, Pan T. N6-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol 2016; 23:98-102; PMID:26840897; http://dx.doi.org/10.1038/nsmb.3162
   PubMed Web of Science ®Google Scholar
• Machnicka MA, Milanowska K, Oglou OO, Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S, Dunin-Horkawicz S, Rother KM, et al. MODOMICS: a database of RNA modification pathways—2013 update. Nucleic Acids Res 2013; 41:D262-D7; PMID:23118484; http://dx.doi.org/10.1093/nar/gks1007
   PubMed Web of Science ®Google Scholar
• Muttach F, Rentmeister A. A Biocatalytic Cascade for Versatile One‐Pot Modification of mRNA Starting from Methionine Analogues. Angewandte Chemie International Edition 2016; 55:1917-20; http://dx.doi.org/10.1002/anie.201507577
   PubMed Web of Science ®Google Scholar
• Vickers TA, Wyatt JR, Burckin T, Bennett CF, Freier SM. Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res 2001; 29:1293-9; PMID:11238995; http://dx.doi.org/10.1093/nar/29.6.1293
   PubMed Web of Science ®Google Scholar
• Xiong Y, Steitz TA. Mechanism of transfer RNA maturation by CCA-adding enzyme without using an oligonucleotide template. Nature 2004; 430:640-5; PMID:15295590; http://dx.doi.org/10.1038/nature02711
   PubMed Web of Science ®Google Scholar
• Cho HD, Verlinde CL, Weiner AM. Reengineering CCA-adding enzymes to function as (U, G)-or dCdCdA-adding enzymes or poly (C, A) and poly (U, G) polymerases. Proc Natl Acad Sci U S A 2007; 104:54-9; PMID:17179213; http://dx.doi.org/10.1073/pnas.0606961104
   PubMed Web of Science ®Google Scholar
• Trippe R, Guschina E, Hossbach M, Urlaub H, Lührmann R, Benecke B-J. Identification, cloning, and functional analysis of the human U6 snRNA-specific terminal uridylyl transferase. RNA 2006; 12:1494-504; PMID:16790842; http://dx.doi.org/10.1261/rna.87706
   PubMed Web of Science ®Google Scholar
• Martin G, Keller W. RNA-specific ribonucleotidyl transferases. RNA 2007; 13:1834-49; PMID:17872511; http://dx.doi.org/10.1261/rna.652807
   PubMed Web of Science ®Google Scholar
• Zamecnik PC, Raychowdhury MK, Tabatadze DR, Cantiello HF. Reversal of cystic fibrosis phenotype in a cultured Δ508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proc Natl Acad Sci U S A 2004; 101:8150-5; PMID:15148387; http://dx.doi.org/10.1073/pnas.0401933101
   PubMed Web of Science ®Google Scholar
• Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation. (2015). Clinical Trial Phase I
   Google Scholar
• Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients. (2015). Clinical Trial Phase IB
   Google Scholar
• Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD). (2014). Clinical Trial Phase II
   Google Scholar
• Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy. (2013). Clinical Trial Phase 2B
   Google Scholar
• A Phase I/II Study of PRO053 in Subjects With Duchenne Muscular Dystrophy (DMD). (2013). Clinical Phase Trial I/II
   Google Scholar
• Study of SRP-4045 and SRP-4053 in DMD Patients (ESSENCE). (2015). Clinical Trial Phase III
   Google Scholar
• A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects. (2015). Clinical Trial Phase I
   Google Scholar
• RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (TNBC-MERIT). (2014). Clinical Trial Phase I
   Google Scholar
• A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients. (2015). Clinical Trial Phase I
   Google Scholar